TICKERNERD
Menu
NSPRNSPRHealthcare · Medical Devices

NSPR Stock Forecast: InspireMD, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$0.48
−5.88% on the day

The 3 Wall Street analysts covering InspireMD, Inc. hold a median 12-month price target of $3 — +525.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$24.6M
Ticker Nerd rank
50 / 100
Median analyst target
$3.00
Analysts covering
3
Revenue$1.8M−0.4% y/y
Operating income−$14.4M
Net income−$14.3M
Free cash flow−$11.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−22.6%
1M
−42.2%
YTD
−73.0%
1Y
−80.3%
From 52W high
−80.3%
From 52W low
0.0%
$0.48
$2.44
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NSPR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores InspireMD, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
50 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
92
Growth
88
Size
87
Volatility
79
Accruals
53
Issuance
42
Quality
13
Momentum
4
Value
1

Revisions (92): Analysts have, on balance, been raising their forecasts.

Value (1): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NSPR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NSPR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Jan 26Apr 26Jul 26Oct 26NSPRHigh $4.00Median $3.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $3.00Median $3.00High $4.00

The green dot is the last close — the median target sits +525.0% from it.

Recent analyst actionsNewest first

Of the 11 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
5 May 2026Piper SandlerReiteratesOverweight$4.00 → $3.00
12 May 2025Piper SandlerMaintainsOverweight—
11 Dec 2024Lake StreetInitiatesBuy—
17 Sept 2024Piper SandlerReiteratesOverweight$4.50
2 Nov 2023Piper SandlerMaintainsOverweight—
12 June 2023Piper SandlerInitiatesOverweight—
17 May 2023National Alliance SecuritiesMaintainsBuy—
31 Mar 2023Alliance Global PartnersMaintainsBuy—
16 Oct 2020Alliance Global PartnersInitiatesBuy$0.70
11 Mar 2020HC Wainwright & Co.ReiteratesBuy$5.00 → $2.00
29 Mar 2016Rodman & RenshawMaintainsBuy$4.00 → $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NSPR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NSPR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, InspireMD, Inc. returned −80.3% against +16.2% for the S&P 500, dividends included.

NSPR vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26NSPRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NSPR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

InspireMD, Inc. (NSPR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 81% of US stocks

Price / sales
2.3×

Cheaper than 49% of US stocks

Price / book
0.8×

Cheaper than 78% of US stocks

EV / EBITDA
0.1×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
−0.4%

Higher than 27% of US stocks

Earnings growth (YoY)
−0.4%

Higher than 36% of US stocks

Gross margin
−43.7%

Higher than 2% of US stocks

Operating margin
−815.6%

Higher than 6% of US stocks

Net margin
29.5%

Higher than 89% of US stocks

Returns & dividend
Return on equity
−202.8%

Higher than 7% of US stocks

Return on assets
−85.8%

Higher than 4% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

InspireMD, Inc. (NSPR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • InspireMD, Inc. has a market value of $24.6M and an enterprise value of −$3.0M.

  • Revenue in the twelve months to 30 June 2026: $10.8M. The latest quarter shrank 0.4% year on year.

  • Net income over the same four quarters: −$52.5M, a −484.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.64.

  • Free cash flow in the twelve months to 30 June 2026: −$42.5M.

  • Shares outstanding: 46.8M.

  • Trailing P/E: −0.7×; forward P/E: −1.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • InspireMD, Inc. employs 127 people — $85K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

NSPR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
NSPRInspireMD, Inc.$24.6M
50
PMIPicard Medical, Inc.$22.6M
24
PAVMPAVmed, Inc.$21.5M
17
MODDModular Medical, Inc.$25.3M
14
BDMDBaird Medical Investment Holdings Ltd.$25.3M
22
LFWDLifeward Ltd.$18.1M
24
ARAYAccuray, Inc.$28.7M
33

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own InspireMD, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NSPR news & analysis

InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million

GlobeNewsWire · 21 Sept 2026neutral

InspireMD announced amendments to certain Series J and Series K warrants that align their trigger event with the anticipated FDA approval of the CGuard Prime 80 cm, which the company continues to expect in Q4 2026. The amendments could provide potential gross proceeds of up to $11 million.

Why it matters — NSPR watchers would care because the warrant amendments tie potential capital to the anticipated CGuard Prime 80 cm FDA approval timeline, which is a key milestone for the company.

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 4 Sept 2026neutral

InspireMD's Compensation Committee approved inducement grants of 23,764 shares of restricted stock to a new non-executive employee, with a grant date of September 2, 2026, issued outside the company's 2021 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — This announcement provides a brief update on InspireMD's equity compensation and hiring activity, which may be of interest to NSPR watchers monitoring corporate governance and staffing developments.

InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 3 Sept 2026neutral

InspireMD, Inc. announced plans to present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference. The company develops the CGuard Prime carotid stent system for stroke prevention.

Why it matters — NSPR watchers would care because the company is increasing investor visibility by presenting at a major investment conference.

InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research · 20 Aug 2026positive

InspireMD (NSPR) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The upgrade signals increased confidence in the company's near-term outlook.

Why it matters — A Zacks upgrade to Buy indicates improved analyst sentiment on InspireMD's earnings outlook, which NSPR watchers would consider a favorable signal.

InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript

Seeking Alpha · 17 Aug 2026neutral

Seeking Alpha published the Q2 2026 earnings call transcript for InspireMD, Inc. (NSPR). The transcript covers the company's second-quarter 2026 results and management discussion during the earnings call.

Why it matters — A NSPR watcher would care because the earnings call transcript provides direct management commentary on the company's latest quarterly performance and outlook.

FAQ

Frequently asked questions about NSPR stock

What is the NSPR stock price forecast for 2026-2027?

The 3 Wall Street analysts covering InspireMD, Inc. have a median 12-month price target of $3, with estimates ranging from $3 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NSPR stock a buy right now?

Of the 3 analysts covering InspireMD, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks InspireMD, Inc. 50 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NSPR?

As at 8 Oct 2026, InspireMD, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (92 of 100).

Will NSPR stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +525.0% from the last close, and Ticker Nerd's factor model ranks InspireMD, Inc. 50 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NSPR stock forecast for 2030?

No analyst covering InspireMD, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NSPR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $4 over the next 12 months.

How has NSPR stock performed over the past year?

InspireMD, Inc. returned -80.3% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does InspireMD, Inc. do?

InspireMD, Inc. is a medical device company that develops and commercializes products for the treatment of carotid artery disease and other vascular conditions.

What is the latest news on NSPR?

The most recent item we track (GlobeNewsWire, 21 Sept 2026): "InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million". InspireMD announced amendments to certain Series J and Series K warrants that align their trigger event with the anticipated FDA approval of the CGuard Prime 80 cm, which the company continues to expect in Q4 2026. The amendments could provide potential gross proceeds of up to $11 million.

Company

About InspireMD, Inc.

InspireMD, Inc. is a medical device company that develops and commercializes products for the treatment of carotid artery disease and other vascular conditions. The company’s portfolio centers on its proprietary CGuard™ carotid stent platform and MicroNet™ mesh technology, which are designed to support embolic protection during and after stenting procedures. InspireMD’s current products include carotid embolic prevention and stent systems used in vascular and neurovascular interventions, with applications across stroke prevention and related artery treatment settings. The company serves physicians, hospitals, and healthcare providers in multiple international markets, including the United States and select regions in Europe, the Middle East, Latin America, and Asia Pacific. InspireMD plays a specialized role in the medical technology market by focusing on device-based solutions for complex carotid and coronary care.

CEO Mr. Marvin L. Slosman · 127 employees · United States · https://www.inspiremd.com